Cytokine modulators in the treatment of sarcoidosis

Bargagli, Elena; Olivieri, Carmela; Rottoli, Paola

doi:10.1007/s00296-011-1969-9

Cited by 16 publications

(13 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Biologic TNF-a antagonists, in particular infliximab, have been effective even in corticosteroid-resistant cases. 143 A therapeutic algorithm for the treatment of cutaneous sarcoidosis based on the limited published literature, reviewed later, and personal experience is included in Fig. 13.…”

Section: Evaluation and Managementmentioning

confidence: 99%

Sarcoidosis

Sanchez

Haimovic

Prystowsky

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Sarcoidosis is a disease characterized by noncaseating granulomatous infiltration of 1 or more organs. In North America, after the lungs and thoracic lymph nodes, the skin is the next most commonly involved organ. Data from multiple studies indicate a coaction between genetic and environmental factors in immunologically susceptible hosts. The disease's many clinical manifestations and course vary greatly and are influenced by race, ethnicity, and gender. In the skin, the lesions of sarcoidosis are classified as specific when noncaseating granulomas are present, and nonspecific when there is an inflammatory reaction pattern devoid of granulomas.

show abstract

Section: Evaluation and Managementmentioning

confidence: 99%

Sarcoidosis

Sanchez

Haimovic

Prystowsky

2015

Dermatologic Clinics

View full text Add to dashboard Cite

show abstract

“…A recent study identified Th17 cells in blood and BAL fluid of patients with active sarcoidosis, suggesting that IL-17-expressing cells may play a role in the alveolitis phase of disease, potentially leading to fibrosis [36,37]. The literature shows that although anticytokine drugs have a rationale based on involvement of various molecules in the pathogenesis of sarcoidosis, there is still no indisputable evidence of their efficacy [39,40].…”

Section: Granuloma Of Sarcoidosis and Cytokines Involved In Pathogenementioning

confidence: 97%

Osseous sarcoidosis: a case series

et al. 2014

View full text Add to dashboard Cite

Sarcoidosis is an inflammatory disorder characterized by noncaseating granulomas infiltrating affected organs. Any organ system can be involved, and more than 90 % of patients have a primary pulmonary manifestation. The incidence of radiographically evident bone involvement has been reported over a wide range: from 3 to 39 % depending on the population studied and imaging modalities used. Any bone may be affected in osseous sarcoidosis. Bilateral involvement of the phalanges of the hand and feet is most common. However, reports of long bone, skull, rib and vertebral involvement have appeared. To date, there are no specific tools for the assessment of skeletal disease activity in sarcoidosis. Plain radiograph picks lesions in the small bones of hands and feet greater than does in other bones. Bone scan is useful for defining the extent of the skeletal disease and bone marrow involvement. Magnetic resonance imaging usually demonstrates multifocal lesions within the vertebrae that are hypointense on T1-weighted images and hyperintense on T2-weighted images. In cases of multifocal bone lesions and an established diagnosis of sarcoidosis, a diagnosis of bone sarcoidosis should be considered in the differential diagnosis. Optimal treatment of osseous sarcoidosis remains controversial. We present five cases of multisystem sarcoidosis with skeletal involvement including long bones and vertebrae and a description of immunosuppressive therapies used in our patients. A literature review highlighting the diagnostic approach using radiographic imaging, as well as treatment strategies, is provided.

show abstract

“…However, a placebo-controlled randomized study conducted to evaluate the safety and effectiveness of infliximab in subjects with chronic pulmonary sarcoidosis has not produced the expected results [57,58]. Another randomized placebo-controlled study suggests that infliximab may be beneficial in the treatment of extrapulmonary sarcoidosis in patients already receiving corticosteroids, but authors found no improvement in patients with ocular disease who received infliximab [59].…”

Section: Sarcoidosismentioning

confidence: 99%

Anti-Tumor Necrosis Factor-α Agents in Noninfectious Uveitis

Gueudry¹,

LeHoang

Bodaghi

2012

New Treatments in Noninfectious Uveitis

View full text Add to dashboard Cite

Anti-tumor necrosis factor-α (anti-TNF-α) agents represent a major breakthrough for the therapeutic management of different autoimmune conditions. Noninfectious uveitis may lead to various sight threatening complications. Hence, from extrapolation of the benefit observed in autoimmune systemic diseases, anti-TNF-α agents are widely used in the treatment of noninfectious uveitis. However, their use remains mostly 'off-label' in this indication, and the lack of evidence from randomized controlled studies limits a rationale choice. This review gives an update on the management of uveitis with TNF-α inhibitors, highlighting important issues, including initiation time, type of molecule, duration of therapy but also major adverse events.

show abstract

Cytokine modulators in the treatment of sarcoidosis

Cited by 16 publications

References 72 publications

Sarcoidosis

Sarcoidosis

Osseous sarcoidosis: a case series

Anti-Tumor Necrosis Factor-α Agents in Noninfectious Uveitis

Contact Info

Product

Resources

About